These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 23920126)

  • 1. A novel antibody-like TCRγδ-Ig fusion protein exhibits antitumor activity against human ovarian carcinoma.
    Zheng J; Guo Y; Ji X; Cui L; He W
    Cancer Lett; 2013 Dec; 341(2):150-8. PubMed ID: 23920126
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficient growth inhibition of ErbB2-overexpressing tumor cells by anti-ErbB2 ScFv-Fc-IL-2 fusion protein in vitro and in vivo.
    Shi M; Zhang L; Gu HT; Jiang FQ; Qian L; Yu M; Chen GJ; Luo Q; Shen BF; Guo N
    Acta Pharmacol Sin; 2007 Oct; 28(10):1611-20. PubMed ID: 17883948
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting solid tumors via T cell receptor complementarity-determining region 3delta in an engineered antibody.
    Wang Z; Zhang T; Hu H; Zhang H; Yang Z; Cui L; He W
    Cancer Lett; 2008 Dec; 272(2):242-52. PubMed ID: 18782650
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination B7-Fc fusion protein treatment and Treg cell depletion therapy.
    Liu A; Hu P; Khawli LA; Epstein AL
    Clin Cancer Res; 2005 Dec; 11(23):8492-502. PubMed ID: 16322313
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined Fc-protein- and Fc-glyco-engineering of scFv-Fc fusion proteins synergistically enhances CD16a binding but does not further enhance NK-cell mediated ADCC.
    Repp R; Kellner C; Muskulus A; Staudinger M; Nodehi SM; Glorius P; Akramiene D; Dechant M; Fey GH; van Berkel PH; van de Winkel JG; Parren PW; Valerius T; Gramatzki M; Peipp M
    J Immunol Methods; 2011 Oct; 373(1-2):67-78. PubMed ID: 21855548
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The anti-tumor efficacy of 3C23K, a glyco-engineered humanized anti-MISRII antibody, in an ovarian cancer model is mainly mediated by engagement of immune effector cells.
    Estupina P; Fontayne A; Barret JM; Kersual N; Dubreuil O; Le Blay M; Pichard A; Jarlier M; Pugnière M; Chauvin M; Chardès T; Pouget JP; Deshayes E; Rossignol A; Abache T; de Romeuf C; Terrier A; Verhaeghe L; Gaucher C; Prost JF; Pèlegrin A; Navarro-Teulon I
    Oncotarget; 2017 Jun; 8(23):37061-37079. PubMed ID: 28427157
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activity of human monocytes in IgE antibody-dependent surveillance and killing of ovarian tumor cells.
    Karagiannis SN; Wang Q; East N; Burke F; Riffard S; Bracher MG; Thompson RG; Durham SR; Schwartz LB; Balkwill FR; Gould HJ
    Eur J Immunol; 2003 Apr; 33(4):1030-40. PubMed ID: 12672069
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tandem-epitope peptide: a novel stimulator for gammadeltaT cells in tumor immunotherapy.
    He X; Chen H; Wu D; Cui L; He W
    Cancer Lett; 2010 Feb; 288(1):86-93. PubMed ID: 19665289
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Binding of divalent H-2Kd/IgG2aFc fusion protein to murine macrophage via Fc-FcR interaction.
    Xiao W; Chen X; Lin Zhou ; Lu S; Liang Z; Wu X
    Cell Mol Immunol; 2007 Apr; 4(2):147-51. PubMed ID: 17571461
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Binding and functional properties of a mouse-human chimeric monoclonal antibody of the human IgG1 subclass with specificity for human carcinomas.
    Liao SK; Horton L; Flahart RE; O'Rear L; Crumpacker D; Imbaratto JW; Yannelli JR; Robinson RR; Oldham RK
    Hum Antibodies Hybridomas; 1990; 1(2):66-76. PubMed ID: 2103354
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improving the efficacy of antibody-interleukin 2 fusion proteins by reducing their interaction with Fc receptors.
    Gillies SD; Lan Y; Lo KM; Super M; Wesolowski J
    Cancer Res; 1999 May; 59(9):2159-66. PubMed ID: 10232603
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhancement of antibody-dependent mechanisms of tumor cell lysis by a targeted activator of complement.
    Imai M; Ohta R; Varela JC; Song H; Tomlinson S
    Cancer Res; 2007 Oct; 67(19):9535-41. PubMed ID: 17909064
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Generation and preclinical characterization of an NKp80-Fc fusion protein for redirected cytolysis of natural killer (NK) cells against leukemia.
    Deng G; Zheng X; Zhou J; Wei H; Tian Z; Sun R
    J Biol Chem; 2015 Sep; 290(37):22474-84. PubMed ID: 26198633
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potent in vitro and in vivo activity of an Fc-engineered anti-CD19 monoclonal antibody against lymphoma and leukemia.
    Horton HM; Bernett MJ; Pong E; Peipp M; Karki S; Chu SY; Richards JO; Vostiar I; Joyce PF; Repp R; Desjarlais JR; Zhukovsky EA
    Cancer Res; 2008 Oct; 68(19):8049-57. PubMed ID: 18829563
    [TBL] [Abstract][Full Text] [Related]  

  • 15. IL-15R alpha-IgG1-Fc enhances IL-2 and IL-15 anti-tumor action through NK and CD8+ T cells proliferation and activation.
    Wu Z; Xu Y
    J Mol Cell Biol; 2010 Aug; 2(4):217-22. PubMed ID: 20671116
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In situ expression of soluble B7-1 in the context of oncolytic herpes simplex virus induces potent antitumor immunity.
    Todo T; Martuza RL; Dallman MJ; Rabkin SD
    Cancer Res; 2001 Jan; 61(1):153-61. PubMed ID: 11196154
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A chimeric humanized single-chain antibody against the type I insulin-like growth factor (IGF) receptor renders breast cancer cells refractory to the mitogenic effects of IGF-I.
    Sachdev D; Li SL; Hartell JS; Fujita-Yamaguchi Y; Miller JS; Yee D
    Cancer Res; 2003 Feb; 63(3):627-35. PubMed ID: 12566306
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic efficacy of a soluble receptor activator of nuclear factor kappaB-IgG Fc fusion protein in suppressing bone resorption and hypercalcemia in a model of humoral hypercalcemia of malignancy.
    Oyajobi BO; Anderson DM; Traianedes K; Williams PJ; Yoneda T; Mundy GR
    Cancer Res; 2001 Mar; 61(6):2572-8. PubMed ID: 11289133
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Asymmetrical Fc engineering greatly enhances antibody-dependent cellular cytotoxicity (ADCC) effector function and stability of the modified antibodies.
    Liu Z; Gunasekaran K; Wang W; Razinkov V; Sekirov L; Leng E; Sweet H; Foltz I; Howard M; Rousseau AM; Kozlosky C; Fanslow W; Yan W
    J Biol Chem; 2014 Feb; 289(6):3571-90. PubMed ID: 24311787
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Binding activities and antitumor properties of a new mouse/human chimeric antibody specific for GD2 ganglioside antigen.
    Alvarez-Rueda N; Leprieur S; Clémenceau B; Supiot S; Sébille-Rivain V; Faivre-Chauvet A; Davodeau F; Paris F; Barbet J; Aubry J; Birklé S
    Clin Cancer Res; 2007 Sep; 13(18 Pt 2):5613s-5620s. PubMed ID: 17875797
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.